Taylor A D, Loxley H D, Flower R J, Buckingham J C
Department of Pharmacology, Charing Cross and Westminster Medical School, London, UK.
Neuroendocrinology. 1995 Jul;62(1):19-31. doi: 10.1159/000126984.
Our recent studies suggest that lipocortin 1 (LC1), a potential mediator of the anti-inflammatory, antiproliferative and anti-fever actions of glucocorticoids in peripheral tissues, may also contribute to the powerful negative feedback actions of the steroids on the hypothalamo-pituitary-adrenal (HPA) axis. In the present study we have used (1) an in vitro model to examine the influence of a specific neutralizing monoclonal anti-LC1 antibody (anti-LC1 mAb) on the capacity of dexamethasone to suppress the cytokine-induced release of the 41-amino acid corticotropin-releasing factor (CRF-41) and arginine vasopressin (AVP) from the rat hypothalamus and (2) a passive immunization protocol to assess the contribution of LC1 to the inhibitory actions of dexamethasone on the HPA responses to immunological (i.p. injection of interleukin 1 beta, IL-1 beta) and surgical (laparotomy under ether anaesthesia) stress. In vitro, Il-1 alpha (0.2 ng/ml), IL-1 beta (0.5 ng/ml), IL-6 (10 ng/ml) and IL-8 (1 ng/ml) each caused significant increases in the release of immunoreactive (ir)-CRF-41 and ir-AVP from hypothalami removed from rats adrenalectomized 10-12 days before autopsy; these responses were readily inhibited by preincubation of the tissue with dexamethasone (10(-7) M). The inhibitory actions of the steroid were attenuated and, in many instances, abolished by inclusion in the medium of a monoclonal anti-LC1 antibody (LC1 mAb, diluted 1:15,000); an isotype-matched control antibody (antispectrin alpha+beta, diluted 1:15,000) was ineffective in this regard. IL-1 alpha (0.2 ng/ml), IL-1 beta (0.5 ng/ml) and IL-6 (10 ng/ml) also initiated similar increases in the release of CRF-41 and AVP from hypothalami from intact rats which were effectively blocked by dexamethasone (10(-7) M). However, although the inhibitory actions of the steroid on the pharmacologically evoked release of CRF-41 were specifically overcome by anti-LC1 mAb (diluted 1:15,000), the steroid blockade of AVP release was not. In vivo, rats pretreated with either a polyclonal anti-LC1 antibody (anti-LC1 pAb, 1 ml/day s.c. for 2 days) or a corresponding volume of a nonimmune sheep serum (NSS) responded to immunological (IL-1 beta, 3 micrograms/kg i.p.) or surgical (laparotomy under ether anaesthesia) trauma with significant increases in the serum ACTH and corticosterone concentrations. In the NSS-treated groups, dexamethasone (100 micrograms/kg), which had no effect on the prestress concentrations of ACTH and corticosterone in the blood, completely prevented the HPA responses to both IL-1 beta and laparotomy.(ABSTRACT TRUNCATED AT 400 WORDS)
我们最近的研究表明,脂皮质素1(LC1)作为糖皮质激素在外周组织中抗炎、抗增殖及退热作用的潜在介质,可能也参与了类固醇对下丘脑-垂体-肾上腺(HPA)轴强大的负反馈作用。在本研究中,我们采用了:(1)一种体外模型,以检测特异性中和单克隆抗LC1抗体(抗LC1 mAb)对地塞米松抑制细胞因子诱导的大鼠下丘脑释放41个氨基酸的促肾上腺皮质激素释放因子(CRF-41)和精氨酸加压素(AVP)能力的影响;(2)一种被动免疫方案,以评估LC1在地塞米松对免疫(腹腔注射白细胞介素1β,IL-1β)和手术(乙醚麻醉下剖腹术)应激的HPA反应抑制作用中的贡献。在体外,白细胞介素1α(0.2 ng/ml)、白细胞介素1β(0.5 ng/ml)、白细胞介素6(10 ng/ml)和白细胞介素8(1 ng/ml)均可使取自尸检前10 - 12天摘除肾上腺大鼠的下丘脑释放免疫反应性(ir)-CRF-41和ir-AVP显著增加;这些反应可通过用地塞米松(10⁻⁷ M)预孵育组织而轻易被抑制。类固醇的抑制作用减弱,并且在许多情况下,通过在培养基中加入单克隆抗LC1抗体(LC1 mAb,稀释1:15,000)而被消除;同种型匹配的对照抗体(抗血影蛋白α + β,稀释1:15,000)在这方面无效。白细胞介素1α(0.2 ng/ml)、白细胞介素1β(0.5 ng/ml)和白细胞介素6(10 ng/ml)也可使完整大鼠下丘脑释放CRF-41和AVP出现类似增加,这可被地塞米松(10⁻⁷ M)有效阻断。然而,尽管抗LC1 mAb(稀释1:15,000)可特异性克服类固醇对CRF-41药理诱导释放的抑制作用,但类固醇对AVP释放的阻断作用却未被克服。在体内,用多克隆抗LC1抗体(抗LC1 pAb,1 ml/天皮下注射,共2天)或相应体积的非免疫绵羊血清(NSS)预处理的大鼠,对免疫(IL-1β,3 μg/kg腹腔注射)或手术(乙醚麻醉下剖腹术)创伤的反应是血清促肾上腺皮质激素(ACTH)和皮质酮浓度显著增加。在NSS处理组中,地塞米松(100 μg/kg)对血液中应激前ACTH和皮质酮浓度无影响,但可完全阻止HPA对IL-1β和剖腹术的反应。(摘要截短于400字)